Microbot Medical (MBOT) Common Equity (2010 - 2026)

Microbot Medical (MBOT) has reported Common Equity for 17 consecutive years, with $74.1 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 155.97% year-over-year to $74.1 million; the trailing twelve-month figure through Mar 2026 stood at $74.1 million (up 155.97% YoY), and the FY2025 full-year result was $77.6 million, up 2097.0% from the prior year.
• Common Equity fell to $74.1 million in Q1 2026 per MBOT's latest filing, from $77.6 million in the prior quarter.
• Across five years, Common Equity topped out at $78.2 million in Q3 2025 and bottomed at $3.5 million in Q4 2024.
• Historically, Common Equity has averaged $21.6 million across 5 years, with a median of $7.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 69.04% in 2022, then soared 2097.0% in 2025.
• Over 5 years, Common Equity stood at $7.3 million in 2022, then slumped by 38.25% to $4.5 million in 2023, then decreased by 21.57% to $3.5 million in 2024, then jumped by 2097.0% to $77.6 million in 2025, then retreated by 4.45% to $74.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $74.1 million, $77.6 million, and $78.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.